CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 80.96% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

Agenus Presents Phase 3 Trial Plans for BOT+BAL in MSS Colon Cancer

By Public Technologies
  • Agenus plans to start its Phase 3 ROBBIN trial of neoadjuvant botensilimab and balstilimab in MSS colon cancer by Q1 2027.
  • The FDA-aligned trial will enroll 850 patients, with event-free survival as its primary endpoint.
  • Across NEST and UNICORN, roughly 30% of 34 MSS patients achieved complete pathological responses; no recurrences occurred among all 52 combination-treated patients.
  • Interim event-free survival analysis is anticipated in the second half of 2029; final analysis is expected in the second half of 2030.
  • PIPE financing is expected to cover all ROBBIN costs and operating expenses through year-end 2031, assuming full warrant exercise.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Agenus Inc. published the original content used to generate this news brief on November 05, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.